RecruitingNCT07177209
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Describing Prescription Patterns in an Ulcerative Colitis Population and Generating an Updated Ulcerative Colitis Treatment Paradigm
Sponsor
Pfizer
Enrollment
4,000 participants
Start Date
Apr 1, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
Eligibility
Min Age: 19 Years
Inclusion Criteria5
- Patient enrolled in IBD registry from 2009
- >18 years at time of diagnosis.
- Diagnosis of Ulcerative Colitis.
- Patient data entered during the study period.
- Minimum duration of data post UC diagnosis (Cohort A: 6 months, Cohort B-D 6 months)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGNon-Interventional Study
As provided in real world practice
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07177209
Related Trials
A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice
NCT0696411319 locations
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT0544256798 locations
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT0718500920 locations
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395175 locations
Predictors of Prognosis in IBD Patients
NCT056530111 location